CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00501891
NCT00501891Phase 2Completed
CompareCT.gov

A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

Duke University·interventional·Posted Jul 16, 2007·Updated May 27, 2013

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Metronomic Temozolomide for Glioblastoma Multiforme. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic temozolomide in malignant glioma patients. The secondary objective will be to determine the safety of Avastin, 10 mg/kg every other week, in combination with metronomic temozolomide in terms of progression-free survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme
CountriesUnited States
CollaboratorsGenentech, Inc., Schering-Plough

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 16, 2007
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2007
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 19.0 years ago

Interventions

Bevacizumabdrug

Bevacizumab administered intravenously 10mg/kg every other week.

Metronomic Temozolomidedrug

Temozolomide 50mg/m2 given orally on a daily basis.